Suppr超能文献

接受定期血液透析治疗患者的凝血-纤溶功能增强。

Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment.

作者信息

Nakamura Y, Chida Y, Tomura S

机构信息

Department of Medicine, Nakano General Hospital, Tokyo, Japan.

出版信息

Nephron. 1991;58(2):201-4. doi: 10.1159/000186415.

Abstract

Thirty-three patients with chronic uremia on regular hemodialysis treatment (RDT) have been studied to determine whether coagulation and fibrinolysis are enhanced or not. We examined predialysis values of coagulation and fibrinolysis parameters including alpha-2-plasmin inhibitor-plasmin complex (alpha 2PIC), a good index of in vivo plasmin production, and cross-linked fibrin degradation products (XL-FDP), an index of fibrinolysis secondary to coagulation. Fibrinogen was significantly higher (p less than 0.001) in RDT patients than in normal controls. ATIII activity was significantly lower in RDT patients than in normal controls (p less than 0.001). Plasminogen activity and alpha-2-plasmin inhibitor (alpha 2PI) activity were significantly lower (p less than 0.001) in RDT patients than in normal controls. Alpha 2PIC and XL-FDP were both significantly higher (p less than 0.001) in RDT patients than in normal controls. XL-FDP was inversely correlated with alpha 2PI (r = -0.486, p less than 0.01) and positively correlated with alpha 2PIC (r = 0.646, p less than 0.001). These results suggest that coagulation and fibrinolysis are enhanced in RDT patients and that the enhanced fibrinolysis is mainly due to fibrinolysis secondary to coagulation.

摘要

对33例接受常规血液透析治疗(RDT)的慢性尿毒症患者进行了研究,以确定凝血和纤溶是否增强。我们检测了凝血和纤溶参数的透析前值,包括α-2-纤溶酶抑制剂-纤溶酶复合物(α2PIC),这是体内纤溶酶产生的良好指标,以及交联纤维蛋白降解产物(XL-FDP),这是凝血继发纤溶的指标。RDT患者的纤维蛋白原显著高于正常对照组(p<0.001)。RDT患者的抗凝血酶III(ATIII)活性显著低于正常对照组(p<0.001)。RDT患者的纤溶酶原活性和α-2-纤溶酶抑制剂(α2PI)活性显著低于正常对照组(p<0.001)。RDT患者的α2PIC和XL-FDP均显著高于正常对照组(p<0.001)。XL-FDP与α2PI呈负相关(r = -0.486,p<0.01),与α2PIC呈正相关(r = 0.646,p<0.001)。这些结果表明,RDT患者的凝血和纤溶增强,且增强的纤溶主要是由于凝血继发的纤溶。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验